Biogen CEO on FDA approval for its Alzheimer's drug - YouTube
Aducanumab: New Medication FDA Approved for Alzheimer's Disease – Psychiatry Education Forum
Aduhelm safety: the data gap on aducanumab's brain swelling side effect
June 7, 2021: A Historic Day | The Long and Winding Road...
The Future of Alzheimer's Treatment? Approval of Aduhelm & Other Anti-Amyloid Antibodies – Montgomery County Medical Society
James Deardorff on X: ""Biogen Plans Regulatory Filing for Aducanumab in Alzheimer's Disease" - Hmm... 1. https://t.co/k7Ga4ja0br 2. https://t.co/5cr8gYW72s https://t.co/7NboyUVjWr" / X
Biogen stuns with planned US FDA filing for previously scrapped Alzheimer's drug | S&P Global Market Intelligence
The Science of Aging: Summer 2020 – The Science of Aging
After disastrous start to launch, Biogen still expects 'minimal' sales from Aduhelm this year | Fierce Pharma
The antibody aducanumab reduces Aβ plaques in Alzheimer's disease | Nature
EISAI PRESENTED NEW ANALYSES OF ARIA AND QOL ON LECANEMAB IN CLARITY AD AT THE AD/PD™ 2023 ANNUAL MEETING
Biogen gives up seeking European approval for aducanumab - Drug Discovery and Development
FDA approves much-debated Alzheimer's drug panned by experts | AP News
U.S. approval of Biogen Alzheimer's drug sends shares soaring, hailed as 'big day" for patients | Reuters
With Spotlight on Alzheimer's Disease and Biogen, Competitors' Stocks Soar | BioSpace
Aduhelm (aducanumab) Q+A - Penn Memory Center
Biogen Plans Regulatory Filing for Aducanumab in Alzheimer's Disease Based on New Analysis of Larger Dataset from Phase 3 Studies | Biogen
Biogen Reverses Take on Aducanumab Trial Data | MedPage Today
FDA approves Aduhelm, first new drug for Alzheimer's in 20 years, despite questions - CBS News
FDA's Approval of Biogen's New Alzheimer's Drug Has Huge Cost Implications for Medicare and Beneficiaries | KFF
Biogen's Aducanumab: A Look at the Drug's History and Recent Updates | BioSpace
EMA gives thumbs down to Biogen's Alzheimer's drug aducanumab - Drug Discovery and Development
Congressional Investigation into Alzheimer's Drug Aduhelm Faults the F.D.A. and Biogen - The New York Times
Biogen releases long-term Aduhelm data
/cloudfront-us-east-2.images.arcpublishing.com/reuters/YOZVWDX35VKEVCOQV4LDNO3ZTQ.jpg "U.S. approval of Biogen Alzheimer's drug sends shares soaring, hailed as 'big day\" for patients | Reuters")
U.S. approval of Biogen Alzheimer's drug sends shares soaring, hailed as 'big day" for patients | Reuters
